See more : Gold Resource Corp (GIH.DE) Income Statement Analysis – Financial Results
Complete financial analysis of Agenus Inc. (AGEN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Agenus Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Nu Holdings Ltd. (NU) Income Statement Analysis – Financial Results
- Wajax Corporation (WJX.TO) Income Statement Analysis – Financial Results
- Shandong Huapeng Glass Co.,Ltd. (603021.SS) Income Statement Analysis – Financial Results
- StepStone Group Inc. (STEP) Income Statement Analysis – Financial Results
- Priority Income Fund, Inc. (PRIF-PL) Income Statement Analysis – Financial Results
Agenus Inc. (AGEN)
About Agenus Inc.
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, the company develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS, as well as in clinical stage to treat hematological malignancies and multiple myeloma/B cells; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. operates under ASV, Agenus, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 156.31M | 98.02M | 295.67M | 88.17M | 150.05M | 36.78M | 42.88M | 22.57M | 24.82M | 6.98M | 3.05M | 15.96M | 2.76M | 3.36M | 3.33M | 2.65M | 5.55M | 692.14K | 629.98K | 707.07K | 4.45M | 3.41M | 4.56M | 442.63K | 100.00K |
| Cost of Revenue | 237.68M | 197.26M | 182.08M | 144.97M | 168.34M | 124.60M | 116.13M | 94.97M | 70.44M | 22.35M | 13.54M | 11.24M | 0.00 | 122.95K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.80K | 1.94M | 1.34M | 1.06M | -1.31M | 0.00 |
| Gross Profit | -81.37M | -99.24M | 113.59M | -56.80M | -18.29M | -87.82M | -73.25M | -72.40M | -45.63M | -15.37M | -10.50M | 4.72M | 2.76M | 3.24M | 3.33M | 2.65M | 5.55M | 692.14K | 629.98K | 702.27K | 2.51M | 2.07M | 3.49M | 1.76M | 100.00K |
| Gross Profit Ratio | -52.05% | -101.24% | 38.42% | -64.42% | -12.19% | -238.74% | -170.83% | -320.73% | -183.85% | -220.32% | -344.70% | 29.60% | 100.00% | 96.34% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 99.32% | 56.37% | 60.80% | 76.64% | 396.55% | 100.00% |
| Research & Development | 234.57M | 16.98M | 178.61M | 142.62M | 168.34M | 124.60M | 116.13M | 94.97M | 70.44M | 22.35M | 13.01M | 10.57M | 11.02M | 12.88M | 16.90M | 20.66M | 21.79M | 28.64M | 47.08M | 41.72M | 48.53M | 39.98M | 31.36M | 17.58M | 11.00M |
| General & Administrative | 78.74M | 81.01M | 76.36M | 59.22M | 46.04M | 37.34M | 33.74M | 33.13M | 28.37M | 21.25M | 14.48M | 11.47M | 10.82M | 12.11M | 14.11M | 19.83M | 21.29M | 21.29M | 25.87M | 25.78M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 187.00 | 0.00 | 0.00 | 0.00 | -4.25M | -401.00 | 1.60M | 360.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 78.74M | 81.01M | 76.36M | 59.22M | 46.04M | 37.34M | 33.74M | 33.13M | 28.37M | 21.25M | 14.48M | 11.47M | 10.82M | 12.11M | 14.11M | 19.83M | 17.04M | 21.29M | 27.46M | 25.78M | 21.72M | 19.47M | 13.76M | 9.19M | 6.90M |
| Other Expenses | -235.13M | -16.98M | 5.05M | -1.86M | -168.34M | -2.18M | -16.89M | -19.52M | -7.18M | 835.00K | -5.09M | -4.58M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.68M | 1.00M |
| Operating Expenses | 78.18M | 81.01M | 76.36M | 59.22M | 46.04M | 37.34M | 33.74M | 33.13M | 28.37M | 21.25M | 14.48M | 11.47M | 21.84M | 24.99M | 31.01M | 40.49M | 38.83M | 49.93M | 74.54M | 67.50M | 70.24M | 59.45M | 45.12M | 28.44M | 18.90M |
| Cost & Expenses | 315.86M | 278.27M | 258.44M | 204.18M | 214.38M | 161.94M | 149.87M | 128.10M | 98.81M | 43.60M | 28.03M | 22.70M | 21.84M | 25.11M | 31.01M | 40.49M | 38.83M | 49.93M | 74.54M | 67.51M | 72.18M | 60.79M | 46.18M | 27.13M | 18.90M |
| Interest Income | 0.00 | 61.86M | 65.72M | 61.08M | 41.45M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.93K | 23.34K | 18.79K | 37.56K | 137.48K | 965.84K | 1.47M | 1.88M | 2.77M | 1.46M | 1.17M | 1.59M | 3.37M | 6.18M | 0.00 |
| Interest Expense | 97.93M | 61.86M | 65.72M | 61.08M | 41.45M | 25.27M | 18.87M | 17.32M | 6.60M | 1.26M | 2.43M | 4.72M | 4.21M | 4.87M | 5.34M | 5.08M | 4.99M | 3.29M | 2.96M | 530.88K | 247.07K | 365.17K | 690.00K | 424.65K | 0.00 |
| Depreciation & Amortization | 13.59M | 6.95M | 6.79M | 7.18M | 6.66M | 6.29M | 6.01M | 4.95M | 14.20M | 1.58M | 586.34K | 1.62M | 2.25M | 3.44M | 4.11M | 4.67M | 5.42M | 5.66M | 5.59M | 4.81M | 6.49M | 5.47M | 4.15M | 1.68M | 1.00M |
| EBITDA | -145.92M | -161.85M | 44.02M | -114.63M | -63.45M | -130.48M | -95.82M | -104.73M | -84.71M | -39.64M | -27.06M | -4.98M | -16.81M | -13.60M | -20.86M | -37.84M | -26.39M | -42.94M | -65.55M | -63.41M | -60.48M | -51.91M | -37.48M | -25.01M | -17.86M |
| EBITDA Ratio | -93.35% | -163.96% | 16.60% | -125.54% | -38.42% | -329.09% | -256.96% | -458.83% | -271.16% | -428.88% | -820.36% | -42.23% | -610.95% | -684.45% | -751.05% | -1,787.80% | -501.73% | -6,118.81% | -10,845.01% | -8,359.77% | -1,396.34% | -1,529.55% | -63.27% | 178.59% | -17,800.00% |
| Operating Income | -159.55M | -179.43M | 42.28M | -117.24M | -70.14M | -123.82M | -103.80M | -107.48M | -80.70M | -43.32M | -24.98M | -6.74M | -19.09M | -21.75M | -27.68M | -37.84M | -33.28M | -50.61M | -73.91M | -69.69M | -67.74M | -57.37M | -41.63M | -26.69M | -18.80M |
| Operating Income Ratio | -102.07% | -183.04% | 14.30% | -132.96% | -46.74% | -336.62% | -242.09% | -476.13% | -325.18% | -620.91% | -820.36% | -42.23% | -692.61% | -647.47% | -830.19% | -1,427.48% | -599.35% | -7,312.63% | -11,732.77% | -9,855.80% | -1,522.25% | -1,681.80% | -913.87% | -6,028.85% | -18,800.00% |
| Total Other Income/Expenses | -97.89M | -51.23M | -54.47M | -65.66M | -41.42M | -38.22M | -16.89M | -19.52M | -12.57M | 834.71K | -5.09M | -4.58M | -4.19M | -153.77K | -2.82M | 7.04M | -3.52M | -1.27M | -189.55K | 69.69M | 882.79K | -1.96M | -34.60M | -25.80M | 0.00 |
| Income Before Tax | -257.44M | -230.66M | -28.72M | -182.89M | -111.56M | -162.04M | -120.69M | -127.00M | -87.88M | -42.49M | -30.07M | -11.33M | -24.07M | -22.70M | -31.59M | -29.49M | -52.67M | -52.67M | -74.89M | 12.59M | -66.85M | -57.10M | -76.22M | -52.49M | 0.00 |
| Income Before Tax Ratio | -164.69% | -235.31% | -9.72% | -207.43% | -74.35% | -440.53% | -281.48% | -562.60% | -354.12% | -608.94% | -987.62% | -70.95% | -873.29% | -675.58% | -947.54% | -1,112.30% | -948.63% | -7,609.93% | -11,888.35% | 1,780.44% | -1,502.41% | -1,673.82% | -1,673.39% | -11,857.69% | 0.00% |
| Income Tax Expense | 0.00 | 40.86M | 65.97M | 57.24M | 37.58M | -12.95M | -9.19M | -2.99M | -5.39M | 5.12M | -586.34K | -1.62M | 4.19M | 153.77K | -1.47M | -9.15M | 3.52M | 2.64M | 189.70K | 69.54M | -1.80M | -1.50M | 31.91M | 20.04M | -700.00K |
| Net Income | -245.76M | -271.52M | -94.70M | -240.13M | -149.14M | -159.69M | -120.69M | -127.00M | -87.88M | -42.49M | -30.07M | -11.33M | -23.28M | -21.91M | -30.32M | -28.70M | -36.80M | -51.88M | -74.10M | -56.16M | -65.93M | -55.88M | -73.54M | -46.73M | -18.10M |
| Net Income Ratio | -157.22% | -276.99% | -32.03% | -272.35% | -99.39% | -434.14% | -281.48% | -562.60% | -354.12% | -608.94% | -987.62% | -70.95% | -844.63% | -652.05% | -909.36% | -1,082.49% | -662.70% | -7,495.73% | -11,762.88% | -7,942.85% | -1,481.76% | -1,637.92% | -1,614.51% | -10,557.24% | -18,100.00% |
| EPS | -13.75 | -19.27 | -8.27 | -27.84 | -22.10 | -28.83 | -24.53 | -29.17 | -22.47 | -14.22 | -20.21 | -0.48 | -1.17 | -1.36 | -2.30 | -2.72 | -4.75 | -6.80 | -9.76 | -7.54 | -10.15 | -10.19 | -15.68 | -11.37 | -5.99 |
| EPS Diluted | -13.75 | -19.27 | -8.27 | -27.84 | -22.10 | -28.83 | -24.53 | -29.17 | -22.47 | -14.22 | -20.21 | -0.48 | -1.17 | -1.36 | -2.30 | -2.72 | -4.75 | -6.80 | -9.76 | -7.54 | -10.15 | -10.19 | -15.68 | -11.37 | -5.99 |
| Weighted Avg Shares Out | 17.89M | 14.09M | 11.45M | 8.63M | 6.75M | 5.54M | 4.92M | 4.35M | 3.91M | 2.99M | 1.49M | 23.63M | 19.90M | 16.11M | 13.17M | 10.54M | 7.75M | 7.63M | 7.60M | 7.45M | 6.50M | 5.48M | 4.69M | 4.11M | 3.02M |
| Weighted Avg Shares Out (Dil) | 17.89M | 14.09M | 11.45M | 8.63M | 6.75M | 5.54M | 4.92M | 4.35M | 3.91M | 2.99M | 1.49M | 23.63M | 19.90M | 16.11M | 13.17M | 10.54M | 7.75M | 7.63M | 7.60M | 7.45M | 6.50M | 5.48M | 4.69M | 4.11M | 3.02M |
Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs
Agenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment
Faruqi & Faruqi Reminds Agenus Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of the December 16, 2024 - ACHC
Agenus (AGEN) Loses -41.56% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Agenus (AGEN) Loses -41.13% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Down -39.39% in 4 Weeks, Here's Why Agenus (AGEN) Looks Ripe for a Turnaround
Agenus Inc. (AGEN) Q3 2024 Earnings Call Transcript
Agenus (AGEN) Reports Q3 Loss, Lags Revenue Estimates
November 5, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against - AGEN
Shareholders that lost money on Agenus Inc. (AGEN) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
Source: https://incomestatements.info
Category: Stock Reports